The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market study, conducted by USD Analytics, provides a comprehensive analysis of the market, covering over 143 pages. The report describes the product and industry scope, market prognosis, and status for 2025-2034. The market is currently expanding, driven by major companies such as Roche, Biogen, Novartis, Genentech, and Amgen.
The market size is estimated to be $12.8 billion in 2025, with a forecasted annual growth rate (CAGR) of 10.2% to reach $30.7 billion by 2034. The market is segmented by type, including Rituximab, Obinutuzumab, Ofatumumab, and biosimilars, and by application, including oncology and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus.
The report highlights the dominating region as North America and Europe, with Asia-Pacific being the fastest-growing region. Market trends include increased approvals for new indications and improved patient outcomes, driven by expansion into autoimmune markets, biosimilar development, and subcutaneous delivery formats. However, high therapy costs, infusion-related side effects, and biosimilar competition are major challenges.
The report provides an in-depth analysis of market segments, including types and applications, and regional analysis covering North America, South and Central America, Middle East and Africa, Europe, Asia, and Oceania. The report also includes a comprehensive analysis of key manufacturers, including their growth strategies, SWOT analysis, and development plans.
The report’s objectives include analyzing the market’s growth trends, identifying key factors influencing the market, and examining the competitive landscape. The report also includes a five forces and PESTLE analysis, covering political, economic, social, technological, legal, and environmental factors.
Key findings of the report include:
* The global Anti-CD20 Monoclonal Antibodies (MAbs) market is expected to grow at a CAGR of 10.2% from 2025 to 2034.
* The market size is estimated to be $12.8 billion in 2025 and $30.7 billion by 2034.
* North America and Europe are the dominating regions, with Asia-Pacific being the fastest-growing region.
* The market is driven by expansion into autoimmune markets, biosimilar development, and subcutaneous delivery formats.
* High therapy costs, infusion-related side effects, and biosimilar competition are major challenges.
Overall, the report provides a comprehensive analysis of the Global Anti-CD20 Monoclonal Antibodies (MAbs) market, covering market trends, growth drivers, challenges, and key manufacturer analysis.